secwatch.observer — SEC 8-K summary
======================================

Issuer:     Matinas BioPharma Holdings, Inc. (MTNB)
CIK:        0001582554
Form:       8-K
Filed at:   2022-11-02T23:59:59+00:00
Accession:  0001493152-22-030196
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Matinas BioPharma reports Q3 net loss of $5.5M; MAT2203 Phase 2 meets primary endpoint with 95% survival
--------------------------------------------------------------------------------

- Phase 2 EnACT MAT2203 met primary endpoint: 95% 2-week survival; mean EFA 0.30. Overall survival 90% at 18 weeks.
- Phase 3 registration trial planned Q1 2023; expects enrollment ~18 months, topline data H2 2024.
- Cash $33.1M at Sep 30, 2022 (down from $49.6M); sufficient through 2023. Net loss $5.5M ($0.03/sh) vs $6.8M.
- Eric Ende appointed Chairman effective Oct 1, 2022; founding Chairman Conrad remains as independent director.
- Recorded $1.1M revenue from BioNTech collaboration; advanced discussions for license option on LNC platform.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582554/000149315222030196/0001493152-22-030196-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582554/000149315222030196/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-030196

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer